|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricci AD, Rizzo A and Brandi G: DNA damage
response alterations in gastric cancer: Knocking down a new wall.
Future Oncol. 17:865–868. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ricci AD, Rizzo A, Rojas Llimpe FL, Di
Fabio F, De Biase D and Rihawi K: Novel HER2-directed treatments in
advanced gastric carcinoma: AnotHER paradigm shift? Cancers
(Basel). 13:16642021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabernero J, Hoff PM, Shen L, Ohtsu A,
Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K and Kang YK:
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive
metastatic gastric or gastro-oesophageal junction cancer (JACOB):
Final analysis of a double-blind, randomised, placebo-controlled
phase 3 study. Lancet Oncol. 19:1372–1384. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu
JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, et al:
Lapatinib in combination with capecitabine plus oxaliplatin in
human epidermal growth factor receptor 2-positive advanced or
metastatic gastric, esophageal, or gastroesophageal adenocarcinoma:
TRIO-013/LOGiC-A randomized phase III Trial. J Clin Oncol.
34:443–451. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thuss-Patience PC, Shah MA, Ohtsu A, Van
Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G,
Shitara K, et al: Trastuzumab emtansine versus taxane use for
previously treated HER2-positive locally advanced or metastatic
gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An
international randomised, open-label, adaptive, phase 2/3 study.
Lancet Oncol. 18:640–653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rihawi K, Ricci AD, Rizzo A, Brocchi S,
Marasco G, Pastore LV, Llimpe FLR, Golfieri R and Renzulli M:
Tumor-associated macrophages and inflammatory microenvironment in
gastric cancer: Novel translational implications. Int J Mol Sci.
22:38052021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y,
Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of
immune-checkpoint inhibitors in human cancers. Front Immunol.
13:9644422022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Viscardi G, Tralongo AC, Massari F,
Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S,
Imbimbo M, et al: Comparative assessment of early mortality risk
upon immune checkpoint inhibitors alone or in combination with
other agents across solid malignancies: A systematic review and
meta-analysis. Eur J Cancer. 177:175–185. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guidi A, Violati M, Blasi M, Ferrari E,
Luciani A, Codecà C and Ferrari D: Autoimmune-related encephalitis
during treatment with nivolumab for advanced head and neck cancer:
A case report. Tumori. 106:NP23–NP28. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding P, Guo H, Sun C, Yang P, Kim NH, Tian
Y, Liu Y, Liu P, Li Y and Zhao Q: Combined systemic
immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally
advanced gastric cancer patients receiving neoadjuvant chemotherapy
with PD-1 antibody sintilimab and XELOX: A prospective study. BMC
Gastroenterol. 22:1212022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhu JY, Zhou LN, Tang M, Chen MB
and Tao M: Predicting the prognosis of gastric cancer by
albumin/globulin ratio and the prognostic nutritional index. Nutr
Cancer. 72:635–644. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin C, Toiyama Y, Okugawa Y, Omura Y,
Kusunoki Y, Kusunoki K, Imaoka Y, Yasuda H, Ohi M and Kusunoki M:
Clinical significance of advanced lung cancer inflammation index, a
nutritional and inflammation index, in gastric cancer patients
after surgical resection: A propensity score matching analysis.
Clin Nutr. 40:1130–1136. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang FH, Zhang XT, Li YF, Tang L, Qu XJ,
Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: The Chinese society
of clinical oncology (CSCO): Clinical guidelines for the diagnosis
and treatment of gastric cancer, 2021. Cancer Commun (Lond).
41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bossi P, Delrio P, Mascheroni A and
Zanetti M: The spectrum of malnutrition/cachexia/sarcopenia in
oncology according to different cancer types and settings: A
narrative review. Nutrients. 13:19802021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
23
|
Okadome K, Baba Y, Yagi T, Kiyozumi Y,
Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M and Baba
H: Prognostic nutritional index, tumor-infiltrating lymphocytes,
and prognosis in patients with esophageal cancer. Ann Surg.
271:693–700. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang D, Hu X, Xiao L, Long G, Yao L, Wang
Z and Zhou L: Prognostic nutritional index and systemic
immune-inflammation index predict the prognosis of patients with
HCC. J Gastrointest Surg. 25:421–427. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen F, Ma Y, Guo W and Li F: Prognostic
value of geriatric nutritional risk index for patients with
non-small cell lung cancer: A systematic review and meta-analysis.
Lung. 200:661–669. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nogueiro J, Santos-Sousa H, Pereira A,
Devezas V, Fernandes C, Sousa F, Fonseca T, Barbosa E and Barbosa
JA: The impact of the prognostic nutritional index (PNI) in gastric
cancer. Langenbecks Arch Surg. 407:2703–2714. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsubara T, Takamori S, Haratake N,
Toyozawa R, Miura N, Shimokawa M, Yamaguchi M, Seto T and
Takenoyama M: The impact of immune-inflammation-nutritional
parameters on the prognosis of non-small cell lung cancer patients
treated with atezolizumab. J Thorac Dis. 12:1520–1528. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guven DC, Aktepe OH, Taban H, Aktas BY,
Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, et al:
Lower prognostic nutritional index is associated with poorer
survival in patients receiving immune checkpoint inhibitors.
Biomark Med. 15:1123–1130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ishiyama Y, Kondo T, Nemoto Y, Kobari Y,
Ishihara H, Tachibana H, Yoshida K, Hashimoto Y, Takagi T, Iizuka J
and Tanabe K: Predictive impact of prognostic nutritional index on
pembrolizumab for metastatic urothelial carcinoma resistant to
platinum-based chemotherapy. Anticancer Res. 41:1607–1614. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song M, Zhang Q, Song C, Liu T, Zhang X,
Ruan G, Tang M, Xie H, Zhang H, Ge Y, et al: The advanced lung
cancer inflammation index is the optimal inflammatory biomarker of
overall survival in patients with lung cancer. J Cachexia
Sarcopenia Muscle. 13:2504–2514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu H, Ding F, Lin M, Shi Z, Mei Z, Chen S,
Jiang C, Qiu H, Zheng Z, Chen Y and Zhao P: Use of the advanced
lung cancer inflammation index as a prognostic indicator for
patients with cholangiocarcinoma. Front Surg. 9:8017672022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gaudioso P, Borsetto D, Tirelli G,
Tofanelli M, Cragnolini F, Menegaldo A, Fabbris C, Molteni G,
Marchioni D, Nicolai P, et al: Advanced lung cancer inflammation
index and its prognostic value in HPV-negative head and neck
squamous cell carcinoma: A multicentre study. Support Care Cancer.
29:4683–4691. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pian G, Hong SY and Oh SY: Prognostic
value of advanced lung cancer inflammation index in patients with
colorectal cancer liver metastases undergoing surgery. Tumori.
108:56–62. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang X, Wang D, Sun T, Li W and Dang C:
Advanced lung cancer inflammation index (ALI) predicts prognosis of
patients with gastric cancer after surgical resection. BMC Cancer.
22:6842022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mountzios G, Samantas E, Senghas K, Zervas
E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et
al: Association of the advanced lung cancer inflammation index
(ALI) with immune checkpoint inhibitor efficacy in patients with
advanced non-small-cell lung cancer. ESMO Open. 6:1002542021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guven DC, Aktepe OH, Aksun MS, Sahin TK,
Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, et al:
The association between albumin-globulin ratio (AGR) and survival
in patients treated with immune checkpoint inhibitors. Cancer
Biomark. 34:189–199. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hill LA, Bodnar TS, Weinberg J and Hammond
GL: Corticosteroid-binding globulin is a biomarker of inflammation
onset and severity in female rats. J Endocrinol. 230:215–225. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bae YJ and Kratzsch J:
Corticosteroid-binding globulin: Modulating mechanisms of
bioavailability of cortisol and its clinical implications. Best
Pract Res Clin Endocrinol Metab. 29:761–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie HL, Zhang Q, Ruan GT, Ge YZ, Hu CL,
Song MM, Song CH, Zhang X, Zhang XW, Li XR, et al: Evaluation and
validation of the prognostic value of serum albumin to globulin
ratio in patients with cancer cachexia: Results from a large
multicenter collaboration. Front Oncol. 11:7077052021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salciccia S, Frisenda M, Bevilacqua G,
Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S,
Giorgino G, Rosati D, et al: Prognostic value of albumin to
globulin ratio in non-metastatic and metastatic prostate cancer
patients: A meta-analysis and systematic review. Int J Mol Sci.
23:115012022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rong G, Liu S, Xi C, Wang C, Deng J and
Qin T: Correlation between preoperative serum albumin-globulin
ratio and prognosis of patients undergoing low rectal cancer
surgery. Clin Lab. 68:2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oymak E, Guler OC and Onal C: Prognostic
significance of albumin and globulin levels in cervical cancer
patients treated with chemoradiotherapy. Int J Gynecol Cancer.
33:19–25. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gundog M and Basaran H: Pretreatment low
prognostic nutritional index and low albumin-globulin ratio are
predictive for overall survival in nasopharyngeal cancer. Eur Arch
Otorhinolaryngol. 276:3221–3230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu C, Wang W, Meng X, Sun B, Cong Y, Liu
J, Wang Q, Liu G and Wu S: Albumin/globulin ratio is negatively
correlated with PD-1 and CD25 mRNA levels in breast cancer
patients. Onco Targets Ther. 11:2131–2139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lv GY, An L, Sun XD, Hu YL and Sun DW:
Pretreatment albumin to globulin ratio can serve as a prognostic
marker in human cancers: A meta-analysis. Clin Chim Acta.
476:81–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
